Women with recurrent or persistent ovarian cancer wanted for research study
16153
A randomized phase II evaluation of weekly gemcitabine plus pazopanib versus weekly gemictabine alone in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma
Obstetrics & Gynecology
Duska Linda,
UVa Health System, Department of Obstetrics and Gynecology, Division of Gynecologic Oncology seeks Women, 18 and older with recurrent or persistent ovarian cancer for research study. The purpose of the study is to test the efficacy and safety of a novel agent, pazopanib, as an adjunct to a standard treatment, gemcitabine, for recurrent or persistent ovarian cancer. Study involves routine history and physical exam, tumor evaluations with CT scans, and routine blood tests. Participation in this study will continue until disease progression and/or inability to tolerate treatment. ? Experimental medication will be provided free of charge. ? No compensation is provided for this study. Contact Information: For more information please contact: • Sanja Arapovic • 434-924-2745 / su2x@virginia.edu • IRB-HSR # 16153 Principal Investigator: Linda Duska, MD
Adult
Ovarian Cancer
Cancer (Oncology)
Ill
No Compensation
Sanja Arapovic
su2x@virginia.edu
4349242745
